培西他普治疗年龄相关性黄斑变性地图样萎缩36个月以上:来自OAKS、DERBY和GALE研究的数据
GALE开放标签扩展研究12个月结果显示,完成OAKS/DERBY的GA患者继续玻璃体腔注射培西他普至36个月,GA面积变化率较预测假手术降低最多32%,PM-PM组非中心凹GA第一年降低42%。PM-PM组36个月新暗点减少18%(P=0.0156),安全性与此前24个月OAKS/DERBY一致。
要点
- GALE开放标签扩展研究12个月保留率92.0%(727/790),所有眼GA面积变化率较预测假手术降低最多32%。
- PM-PM组非中心凹GA第一年GA面积变化率较预测假手术降低42%,PM-PM组36个月新暗点减少18%(P=0.0156)。
- 安全性:渗出性AMD 33眼(4.5%)、眼内炎症15眼(1.9%)、缺血性视神经病变1眼(0.1%)、感染性眼内炎1眼(0.1%),无血管炎事件。
核心结论
- 培西他普治疗36个月以上持续降低GA面积增长且疗效随时间增加,并减少新暗点形成。
- GALE前12个月培西他普安全性与既往24个月OAKS和DERBY研究一致。
研究设计与样本
- GALE为前瞻性开放标签扩展研究(NCT04770545),随访OAKS(NCT03525613)和DERBY(NCT03525600)24个月假手术对照3期研究。
- 纳入完成OAKS、DERBY或1b期APL2-103(NCT03777332)研究的非中心凹或中心凹GA患者。
- GALE中所有研究眼接受培西他普每月(PM)或隔月(PEOM)给药;OAKS/DERBY中培西他普眼延续原方案(PM-PM和PEOM-PEOM),假手术眼交叉至相同给药间隔(SM-PM和SEOM-PEOM)。
- 评估GALE前12个月安全性和疗效,反映最多36个月连续培西他普治疗。
- 主要结局指标为GA面积平均变化率、微视野暗点总数和不良事件。
主要发现
- GALE前12个月患者保留率为92.0%(727/790)。
- 所有眼(包括非中心凹和中心凹GA)培西他普使GA面积平均变化率较预测假手术降低最多32%。
- GA面积平均变化率降低逐年增加,GALE第一年PM-PM组非中心凹GA眼较预测假手术降低最多42%。
- PM-PM组36个月新暗点减少18%(P=0.0156),为预设微视野分析中的显著影响。
关键数值与推荐
- GA面积平均变化率较预测假手术降低最多32%(所有眼,包括非中心凹和中心凹GA)。
- GALE第一年PM-PM组非中心凹GA眼GA面积平均变化率较预测假手术降低最多42%。
- PM-PM组36个月新暗点减少18%(P=0.0156)。
- 不良事件:渗出性AMD 33眼(4.5%)、眼内炎症15眼(1.9%,严重程度为轻或中度)、缺血性视神经病变1眼(0.1%)、感染性眼内炎1眼(0.1%),无血管炎事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report 12-month results from the GALE open-label extension study (NCT04770545), evaluating up to 36 months of intravitreal pegcetacoplan treatment for geographic atrophy (GA) in age-related macular degeneration (AMD). DESIGN: GALE is a prospective open-label extension study following the 24-month, sham-controlled, phase 3 OAKS (NCT03525613) and DERBY (NCT03525600) studies of pegcetacoplan. PARTICIPANTS: Patients with nonsubfoveal or subfoveal GA who completed OAKS, DERBY, or phase 1b APL2-103 (NCT03777332) studies. METHODS: Pegcetacoplan was administered monthly (PM) or every other month (PEOM) to all study eyes in GALE. Eyes receiving pegcetacoplan in OAKS and DERBY continued the same regimen (PM-PM and PEOM-PEOM), while eyes observed with sham in OAKS and DERBY crossed over to receive pegcetacoplan at the same dosing interval in GALE (SM-PM and SEOM-PEOM). Safety and efficacy through the first 12 months of GALE were assessed, reflecting up to 36 months of continuous pegcetacoplan treatment. MAIN OUTCOME MEASURE: Mean rate of change in GA area, total number of microperimetry scotomatous points, and adverse events. RESULTS: Through the first 12 months of GALE, 92.0% (727/790) patient retention was observed. Across all eyes, including eyes with nonsubfoveal and subfoveal GA, pegcetacoplan reduced the mean rate of change in GA area up to 32% versus projected sham. Year after year, the reductions in the mean rate of change in GA area increased, with up to a 42% reduction observed in eyes with nonsubfoveal GA in the PM-PM group compared with projected sham in the first year of GALE. An 18% reduction in new scotomatous points (P = .0156) was observed with PM-PM at 36 months, highlighting a significant impact in a prespecified microperimetry analysis. Adverse events included 33 (4.5%) eyes with exudative AMD, 15 (1.9%) intraocular inflammation (classified as mild or moderate in severity), 1 (0.1%) ischemic optic neuropathy, and 1 (0.1%) infectious endophthalmitis. No events of vasculitis were reported. CONCLUSION: Over 36 months, pegcetacoplan continued to reduce GA growth with increasing efficacy over time and reduced formation of new scotomatous points. The safety profile of pegcetacoplan in the first 12 months of GALE was consistent with the prior 24-month OAKS and DERBY studies.
引用
- Wykoff CC, Holz FG, Chiang A, et al. Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. Am J Ophthalmol. 2025. PMID: 40280279. doi:10.1016/j.ajo.2025.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。